SOURCE: Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical

March 02, 2011 12:00 ET

Skystar Bio-Pharmaceutical to Present at Upcoming March Investor Conferences

XI'AN, CHINA--(Marketwire - March 2, 2011) -  Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that the Company's management team will be presenting at two upcoming first quarter 2011 conferences: Rodman & Renshaw (NASDAQ: RODM) Annual China Investment Conference in Shanghai, China and Roth Capital's 23rd Annual OC Growth Stock Conference in Dana Point, California.

Rodman & Renshaw Annual China Investment Conference in Shanghai (March 6-8, 2011)

Skystar's investor presentation will be held on Monday, March 7, 2011 at 2:00 PM China standard time or 1:00 AM eastern standard time. The conference will be held at Le Royal Meridien Shanghai. Investors interested in scheduling a one on one meeting with the management team can facilitate a request by contacting the Company at skystar@grayling.com or alternatively contact their Rodman & Renshaw representative directly. For more information about the conference please visit http://www.rodmanandrenshaw.com/conferences?id=61.

Roth Capital's 23rd Annual OC Growth Stock Conference in Dana Point, California (March 13-16, 2011)

Skystar's investor presentation will be held on Wednesday, March 16, 2011 at 8:00 AM pacific daylight time. The conference will be held at the Ritz Carlton, Dana Point, California. Investors interested in scheduling a one on one meeting with the management team can facilitate a request by contacting the Company at skystar@grayling.com or alternatively contact their Roth Capital representative directly. For more information about the conference please visit http://www.roth.com/main/Page.aspx?PageID=7236.

A slide archive of the presentation will be available under the "Events and Presentations" page on the "Investor Relations" section of the Company's website at http://www.ir-site.com/skystar/events.asp.

To request a one-on-one meeting or to be added to Skystar's email list, please contact Christopher Chu at skystar@grayling.com or call 646-284-9426.

To be added to the Company's email distribution for future news releases, please send your request to skystar@grayling.com.

About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines, feed additives) in development and over 240 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

Contact Information

  • Contacts:

    Skystar Bio-Pharmaceutical Company
    Scott Cramer
    Director - Corporate Development and U.S. Representative
    (407) 645-4433

    Grayling

    Investor Relations
    Christopher Chu
    (646)284-9426
    christopher.chu@grayling.com